ArticleFrontiers in endocrinology2023
Development of predictive nomograms clinical use to quantify the risk of diabetic foot in patients with type 2 diabetes mellitus.
Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Establishment and evaluation of a novel tool based on inflammation-nutrition derived biomarkers for early diagnosis of diabetic foot ulcers.Frontiers in immunology · 2026Article
- A nomogram model for predicting risk factors and the outcome of skin ulcer.Annals of medicine · 2025Observational
- Development and validation of a nomogram for predicting diabetic foot ulcer risk in patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2025Article
- Development of an XGBoost-based prediction model for wound recurrence risk in diabetic foot ulcer patients treated with antibiotic-loaded bone cement.Frontiers in endocrinology · 2025Article
- The Metabolic Characteristics of Patients at the Risk for Diabetic Foot Ulcer: A Comparative Study of Diabetic Patients with and without Diabetic Foot.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of the study was to explore the risk factors for diabetic foot disease in patients with type 2 diabetes mellitus and to establish and verify the nomogram model of DF risk in patients with T2DM. Methods: The clinical data of 705 patients with type 2 diabetes who were hospitalized in our hospital from January 2015 to December 2022 were analyzed retrospectively. According to random sampling, the patients were divided into two groups: the training set (DF = 84; simple T2DM = 410) and the verification set (DF = 41; simple T2DM = 170). Univariate and multivariate logistic regression analysis was used to screen the independent risk factors for DF in patients with T2DM in the training set. According to the independent risk factors, the nomogram risk prediction model is established and verified. Results: Logistic regression analysis showed age (OR = 1.093, 95% CI 1.062-1.124, P <0.001), smoking history (OR = 3.309, 95% CI 1.849-5.924, P <0.001), glycosylated hemoglobin (OR = 1.328, 95% CI 1.173-1.502, P <0.001), leukocyte (OR = 1.203, 95% CI 1.076-1.345, and LDL-C (OR = 2.002, 95% CI 1.463-2.740), P <0.001) was independent risk factors for T2DM complicated with DF. The area of the nomogram model based on the above indexes under the ROC curve of the training set and the verification set is 0.827 and 0.808, respectively; the correction curve shows that the model has good accuracy; and the DCA results show that when the risk threshold is between 0.10-0.85 (training set) and 0.10-0.75 (verification set), the clinical practical value of the model is higher. Conclusion: The nomogram model constructed in this study is of high value in predicting the risk of DF in patients with T2DM and is of reference value for clinicians to identify people at high risk of DF and provide them with early diagnosis and individual prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.